Related Experiment Video

Updated: Mar 30, 2026

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

6.4K

Expression Profile of Genes Related to Drug Metabolism in Human Brain Tumors

Pantelis Stavrinou1, Maria-Christina Mavrogiorgou2, Konstantinos Polyzoidis3

  • 1Department of Neurosurgery, University of Cologne, Cologne, Germany.

Plos One
|November 19, 2015
PubMed
Abstract

Insights

Brain tumor subtypes show distinct patterns of drug-metabolizing enzyme expression, with histological type being the primary driver, not malignancy grade. This impacts carcinogen detoxification and susceptibility.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phase I and II enzymes metabolize and detoxify compounds, including carcinogens.
  • Enzyme activity is crucial for inactivating carcinogens and determining susceptibility.
  • Expression of these enzymes in human brain tumors is understudied.

Purpose of the Study:

  • To investigate the association between tumor pathology and the expression of seven phase I and II drug-metabolizing genes and their proteins.
  • To analyze the expression profiles of CYP1A1, CYP1B1, ALDH3A1, AOX1, GSTP1, GSTT1, and GSTM3 in human brain tumors.

Main Methods:

  • Gene and protein expression analyzed using qRT-PCR and western blotting.
  • Study cohort included 77 tumors: meningioma, astrocytoma, and brain metastases (lung adenocarcinoma).

Main Results:

  • Meningeal tumors exhibited higher expression of AOX1, CYP1B1, GSTM3, and GSTP1 (gene and protein levels for AOX1, GSTM3, GSTP1).
  • A negative correlation was found between WHO malignancy grade and expression levels of AOX1, GSTM3, and GSTP1.
  • Gene and protein expression correlation observed for AOX1, GSTP1, and GSTM3 in astrocytomas.

Conclusions:

  • Central nervous system (CNS) tumors display varied drug-metabolizing gene expression patterns.
  • Histological subtype is the predominant factor influencing enzyme expression, more so than malignancy grade.
  • Findings suggest subtype-specific roles in detoxification and carcinogen susceptibility within CNS tumors.

More Related Videos

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

606
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.6K

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
112
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K